266 related articles for article (PubMed ID: 30794381)
1. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
[TBL] [Abstract][Full Text] [Related]
2. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
3. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
4. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
Rab MAE; van Oirschot BA; Bos J; Merkx TH; van Wesel ACW; Abdulmalik O; Safo MK; Versluijs BA; Houwing ME; Cnossen MH; Riedl J; Schutgens REG; Pasterkamp G; Bartels M; van Beers EJ; van Wijk R
Am J Hematol; 2019 May; 94(5):575-584. PubMed ID: 30784099
[TBL] [Abstract][Full Text] [Related]
5. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
[TBL] [Abstract][Full Text] [Related]
6. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
Oder E; Safo MK; Abdulmalik O; Kato GJ
Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
[TBL] [Abstract][Full Text] [Related]
8. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
[TBL] [Abstract][Full Text] [Related]
9. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
[No Abstract] [Full Text] [Related]
10. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.
Estepp JH
Am J Hematol; 2018 Mar; 93(3):326-329. PubMed ID: 29352729
[No Abstract] [Full Text] [Related]
11. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
[TBL] [Abstract][Full Text] [Related]
13. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
Kassa T; Strader MB; Nakagawa A; Zapol WM; Alayash AI
Metallomics; 2017 Sep; 9(9):1260-1270. PubMed ID: 28770911
[TBL] [Abstract][Full Text] [Related]
14. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.
Hebbel RP; Hedlund BE
Am J Hematol; 2018 Mar; 93(3):321-325. PubMed ID: 29150874
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J
Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314
[TBL] [Abstract][Full Text] [Related]
16. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.
Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS
Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477
[TBL] [Abstract][Full Text] [Related]
17. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
[TBL] [Abstract][Full Text] [Related]
18. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
[TBL] [Abstract][Full Text] [Related]
19. Two drugs for sickle cell disease.
Med Lett Drugs Ther; 2020 Apr; 62(1595):51-52. PubMed ID: 32324178
[No Abstract] [Full Text] [Related]
20. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
